Printer Friendly

MAXWELL STAKE IN AFFYMAX SOLD

 MAXWELL STAKE IN AFFYMAX SOLD
 AMSTERDAM, June 30 /PRNewswire/ -- Affymax N.V. announced today that


purchasers led by investors who have been shareholders since the company was privately held, have acquired the 691,562 shares of Affymax that were previously owned by Maxwell Communication Corporation plc. These shares, which represent approximately 4.5 percent of Affymax's outstanding shares, were acquired in an off-market transaction managed by Wertheim Schroder & Co.
 Affymax (NASDAQ: AFMXF), a Netherlands corporation headquartered in Amsterdam, is developing new technologies to accelerate the pace of drug discovery and has additional research programs in diagnostic products and chemical process technology. Affymax is applying these technologies across a broad range of diseases to discover and develop products independently and in collaboration with established pharmaceutical companies. The majority of the company's research and development activities are performed by its wholly owned subsidiary, Affymax Research Institute, located in Palo Alto, Calif.
 -0- 6/30/92
 /CONTACT: Diana Kapp or David Singer of Affymax, 415-496-2300/
 (AFMXF) CO: Affymax ST: California IN: MTC SU:


RM -- SJ002 -- 5142 06/30/92 11:23 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 30, 1992
Words:179
Previous Article:AFGE COMMENDS HOUSE FOR PASSING BILL MAKING THE SOCIAL SECURITY ADMINISTRATION AN INDEPENDENT AGENCY
Next Article:ENDOTRONICS, INC. RECEIVES $2 MILLION LINE OF CREDIT
Topics:


Related Articles
AFFYMAX ANNOUNCES INITIAL PUBLIC OFFERING OF 4,000,000 SHARES OF COMMON STOCK
AFFYMAX ANNOUNCES UNDERWRITERS HAVE EXERCISED OVER-ALLOTMENT OPTION OF 600,000 SHARES
AFFYMAX N.V. ANNOUNCES RESEARCH AGREEMENT WITH JOHNSON & JOHNSON
MAXWELL STAKE IN AFFYMAX SOLD /FOLLOWING IS REPEAT OF RELEASE MOVED EARLIER/
MARION MERRELL DOW COMMITS TO MAJOR EXPANSION OF AFFYMAX ALLIANCE
AFFYMAX RECEIVES $2.2 MILLION NIH HUMAN GENOME GRANT
AFFYMAX RECEIVES $2.2 MILLION NIH HUMAN GENOME GRANT
AFFYMETRIX RECEIVES $500,000 PHASE II SBIR GRANT
AFFYMAX AWARDED FIRST U.S. PATENT FOR RECOMBINANT PEPTIDE DIVERSITY TECHNOLOGY

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters